Bumame
Preventive healthcare and diagnostics for the Indonesian market.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Seed | |
| Total Funding | 000k | ||
Bumame is an Indonesian healthtech company that provides a range of healthcare services, from diagnostic tests to preventative care. Founded in 2020 by James Wihardja, the company initially focused on providing COVID-19 testing services in response to the pandemic.
Building on its initial success, Bumame has since pivoted to address other critical healthcare areas in Indonesia. The company now offers a wide array of services including non-invasive prenatal testing (NIPT), early cancer screenings, and general medical check-ups. Their services cater to both individuals (B2C) and other businesses (B2B2C), with offerings for mother and child care, fertility tests, and wellness solutions like vitamin drips.
Bumame operates on a digital-first model, allowing users to book services online and monitor test results through a mobile application. It provides services through walk-in clinics and at-home appointments, emphasizing convenience and accessibility for its customers. In early 2025, the company secured an undisclosed amount in a pre-Series A funding round led by Alpha JWC Ventures, with participation from 500 Global and Kopital Ventures, to accelerate its digital transformation and expand its service offerings.
Keywords: healthtech, diagnostics, preventative care, medical check-ups, non-invasive prenatal testing, NIPT, cancer screening, home healthcare, digital health, Indonesia healthcare, lab tests, pathology services, DNA testing, corporate health, mobile healthcare, online booking, medical services, wellness